Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1971 1
1972 3
1973 2
1974 2
1975 2
1976 2
1977 12
1978 4
1979 10
1980 4
1981 7
1982 13
1983 8
1984 9
1985 6
1986 4
1987 13
1988 14
1989 4
1990 6
1991 11
1992 9
1993 5
1994 8
1995 8
1996 7
1997 14
1998 8
1999 6
2000 7
2001 6
2002 12
2003 8
2004 9
2005 11
2006 15
2007 11
2008 15
2009 18
2010 19
2011 18
2012 18
2013 16
2014 12
2015 22
2016 17
2017 15
2018 24
2019 21
2020 22
2021 19
2022 23
2023 16
2024 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

554 results

Results by year

Filters applied: . Clear all
Page 1
Cyclophosphamide versus placebo in scleroderma lung disease.
Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M; Scleroderma Lung Study Research Group. Tashkin DP, et al. N Engl J Med. 2006 Jun 22;354(25):2655-66. doi: 10.1056/NEJMoa055120. N Engl J Med. 2006. PMID: 16790698 Free article. Clinical Trial.
Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage Chronic Obstructive Pulmonary Disease.
Madapoosi SS, Cruickshank-Quinn C, Opron K, Erb-Downward JR, Begley LA, Li G, Barjaktarevic I, Barr RG, Comellas AP, Couper DJ, Cooper CB, Freeman CM, Han MK, Kaner RJ, Labaki W, Martinez FJ, Ortega VE, Peters SP, Paine R, Woodruff P, Curtis JL, Huffnagle GB, Stringer KA, Bowler RP, Esther CR Jr, Reisdorph N, Huang YJ; SPIROMICS Research Group. Madapoosi SS, et al. Am J Respir Crit Care Med. 2022 Aug 15;206(4):427-439. doi: 10.1164/rccm.202110-2241OC. Am J Respir Crit Care Med. 2022. PMID: 35536732 Free PMC article.
Marijuana and Lung Disease.
Tashkin DP. Tashkin DP. Chest. 2018 Sep;154(3):653-663. doi: 10.1016/j.chest.2018.05.005. Epub 2018 May 17. Chest. 2018. PMID: 29778658 Review.
Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD.
Fortis S, Quibrera PM, Comellas AP, Bhatt SP, Tashkin DP, Hoffman EA, Criner GJ, Han MK, Barr RG, Arjomandi M, Dransfield MB, Peters SP, Dolezal BA, Kim V, Putcha N, Rennard SI, Paine R 3rd, Kanner RE, Curtis JL, Bowler RP, Martinez FJ, Hansel NN, Krishnan JA, Woodruff PG, Barjaktarevic IZ, Couper D, Anderson WH, Cooper CB; Subpopulations and Intermediate Outcome Measures in COPD Study Investigators. Fortis S, et al. Among authors: tashkin dp. Chest. 2023 Mar;163(3):502-514. doi: 10.1016/j.chest.2022.11.009. Epub 2022 Nov 15. Chest. 2023. PMID: 36395858 Free PMC article.
Longitudinal Follow-Up of Participants With Tobacco Exposure and Preserved Spirometry.
McKleroy W, Shing T, Anderson WH, Arjomandi M, Awan HA, Barjaktarevic I, Barr RG, Bleecker ER, Boscardin J, Bowler RP, Buhr RG, Criner GJ, Comellas AP, Curtis JL, Dransfield M, Doerschuk CM, Dolezal BA, Drummond MB, Han MK, Hansel NN, Helton K, Hoffman EA, Kaner RJ, Kanner RE, Krishnan JA, Lazarus SC, Martinez FJ, Ohar J, Ortega VE, Paine R 3rd, Peters SP, Reinhardt JM, Rennard S, Smith BM, Tashkin DP, Couper D, Cooper CB, Woodruff PG. McKleroy W, et al. Among authors: tashkin dp. JAMA. 2023 Aug 1;330(5):442-453. doi: 10.1001/jama.2023.11676. JAMA. 2023. PMID: 37526720 Free PMC article.
554 results